Effectiveness and Safety of Immunomodulators With Anti–Tumor Necrosis Factor Therapy in Crohn’s Disease-Reference-Cited by-同舟云学术

Effectiveness and Safety of Immunomodulators With Anti–Tumor Necrosis Factor Therapy in Crohn’s Disease

Published:2015-07 Issue:7 Volume:13 Page:1293-1301.e5
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Osterman Mark T.,Haynes Kevin,Delzell Elizabeth,Zhang Jie,Bewtra Meenakshi,Brensinger Colleen M.,Chen Lang,Xie Fenglong,Curtis Jeffrey R.,Lewis James D.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Infliximab, azathioprine, or combination therapy for Crohn’s disease;Colombel;N Engl J Med,2010

2. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial;Van Assche;Gastroenterology,2008

3. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials;Lichtenstein;Aliment Pharmacol Ther,2009

4. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy;Sokol;Gut,2011

5. Does co-treatment with immunosuppressors improve outcome in patients with Crohn’s disease treated with adalimumab?;Reenaers;Aliment Pharmacol Ther,2012

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy;Internal Medicine Journal;2024-09-05

2. Perceptions Toward Established and Novel Dietary Therapies for Crohn’s Disease Management Among Adult Patients: Results From a Questionnaire Survey;Crohn's & Colitis 360;2024-01-01

3. Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial;Clinical Drug Investigation;2023-04

4. Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States;BMC Gastroenterology;2023-03-09

5. Combination therapy in inflammatory bowel disease: Current evidence and perspectives;International Immunopharmacology;2023-01